5 amino 1mq vs tesofensine FAQ

Tesofensine's dopaminergic and serotonergic activity complicates its use in populations with psychiatric histories. The compound was originally developed as an antidepressant, and though it failed that indication, it still modulates CNS reward pathways. Researchers must screen for substance use history and current SSRI/SNRI use to avoid serotonin syndrome. 5-Amino-1MQ has no psychoactive properties and poses no contraindication for mood disorder populations.

5-Amino-1MQ is the appropriate choice. Its mechanism. NNMT inhibition leading to increased NAD+ and mitochondrial fat oxidation. Doesn't involve CNS appetite pathways. Preclinical data shows weight reduction occurs even in ad libitum feeding conditions, meaning caloric intake isn't restricted. This makes it suitable for studies exploring metabolic flexibility, substrate utilisation shifts, or interventions where maintaining normal eating behaviour is essential.

Avoid tesofensine. The Phase 2 trial documented consistent heart rate increases of 7–9 bpm and modest systolic BP elevations across all dose groups. Effects that require regular cardiovascular assessment. 5-Amino-1MQ, by contrast, showed no cardiovascular signals in animal studies and doesn't engage sympathomimetic pathways. For protocols without cardiac monitoring infrastructure, 5-Amino-1MQ is the safer metabolic intervention.

Verify baseline NNMT expression levels. The compound only produces metabolic effects in contexts where NNMT is overexpressed and actively depleting NAD+. Participants with normal or low NNMT activity won't experience substrate-level changes. Measure NAD+/NADH ratios via blood metabolomics if possible. Adjust dose upward cautiously (rodent studies used 50–100mg/kg; human equivalent dosing remains unclear). If no effect persists after 4–6 weeks at increased dose, the research question may require a different intervention targeting NAD+ synthesis directly (e.g., NMN or NR supplementation).

Reduce dose immediately. The Phase 2 trial showed dose-dependent cardiovascular effects, with 0.25mg producing significantly lower BP and HR increases than 0.5mg or 1.0mg. If side effects persist at reduced dose, discontinue and consider whether the research question can be addressed with GLP-1 analogs instead, which produce appetite suppression through gastric emptying delay rather than CNS stimulation. Participants with any history of hypertension, arrhythmia, or stimulant sensitivity should be excluded from tesofensine protocols entirely.

Combine the compounds in separate administration protocols with staggered timing. 5-Amino-1MQ dosed in the morning to align with circadian NAD+ synthesis patterns, tesofensine dosed 30–60 minutes before the largest meal to maximize satiety effect. Monitor cardiovascular parameters (heart rate, blood pressure) more frequently than either compound alone would require, given tesofensine's sympathomimetic effects. Document interaction effects separately from individual compound effects. No published interaction data exists, so any combined protocol is investigational by definition.